ArticleLasers in medical science2025
Harnessing optics and statistics for early detection and prognosis in breast and ovarian cancer.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bilateral Breast Fibroadenoma With Bilateral Ductal Carcinoma In Situ: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Environmental factors are responsible for 90% of cancers and breast cancer is the most common cancers occurring worldwide. The 18th most frequent cancer is ovarian cancer and sixth most frequent cancer in the world is liver cancer. Why we have chosen this study. Early prognosis and therapeutic development for cancer is the main goal of this manuscript through optics and Pearson correlation tools. Polarimetry is used to quantify biochemical and characterize tissues, especially for cancer prognosis. Four polarimetric parameters total (diattenuation, depolarization and retardance) and orientation that have elevated values for malignant and low values for benign for both breast cancer and ovarian cancers. Most of blood parameters and components show attenuation for both cancers under Cefexime. Size of WBCs fluctuates between6.1-9.2 (µm) for breast cancer and 6.0-8.5 (µm) for ovarian cancer. WBCs show strong correlation with bilirubin total (r = 0.2829, p = 0.000) and creatinine (r = 0.2384, p = 0.000) for breast cancer, RBCs have positive correlation with SGPT (r = 0.1872, p = 0.022) and T. Bilirubin (r = 0.1585, p = 0.000) for breast cancer. Serum creatinine with RBCs (r = 0.113, p = 0.000) and SGPT only with MCV (r = 0.6814, p = 0.000) show very strong positive correlation for liver cancer. Thus polarimetric properties especially retardance and depolarization can be used for early prognosis / diagnose of cancer.Clinical trial number Not applicable.
Indexed as
Identifiers
40515796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.